580 692
a prospective, randomized, multicenter study. Int Urol Nephrol
2014;46:523–9
.
[31]
Seo DH, Kam SC, Hyun JS. Impact of lower urinary tract symptoms/ benign prostatic hyperplasia treatment with tamsulosin and soli- fenacin combination therapy on erectile function. Korean J Urol 2011;52:49–54.
[32]
van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 2013;64:1003–12.
[33]
Van Kerrebroeck P, Haab F, Angulo JC, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol 2013;64:398–407.[34]
Yamaguchi O, Kakizaki H, Homma Y, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms—ASSIST, randomized controlled study. Urology 2011;78:126–33.
[35]
Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009;56:534–41.
[36]
Kaplan SA, Roehrborn CG, Rovner ES, CarlssonM, BavendamT, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319–28.
[37]
Lee SH, Chung BH, Kim SJ, Kim JH, Kim JC, Lee JY. Initial combined treatment with anticholinergics and alpha-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis 2011;14: 320–5.
[38]
Memon I, Javed A, Pirzada AJ, Abdullah A, Ali S, Ahmed SF. Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyper- plasia (BPH) having irritative (overactive bladder) symptoms. Rawal Med J 2014;39:421–4.
[39]
Malkoc E, Ates F, Senkul T, Adayener C, SoydanH, Baykal KV. Additive role of trospium chloride in the management of men with voiding and storage symptoms. Turk Klin TIP BILIM 2012;32:1374–80.
[40]
Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol 2014;193: 921–6.[41]
Singh DV, Mete UK, Mandal AK, Singh SK. A comparative random- ized prospective study to evaluate efficacy and safety of combina- tion of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med 2014;11:187–96.
[42]
Yokoyama O, Yoshida M, Kim SC, et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. Int J Urol 2013;20:193–201.[43]
Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an inter- national, randomized, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917–25.
[44]
Kim SC, Park JK, Kim SW, et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using tamsulosin as an active control. Low Urin Tract Symptoms 2011;3:86–93.
[45]
Kumar S, Kondareddy C, Ganesamoni R, Nanjappa B, Singh SK. Randomized controlled trial to assess the efficacy of the combina- tion therapy of alfuzosin and tadalafil in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Low Urin Tract Symptoms 2014;6:35–40.[46]
Liguori G, Trombetta C, De Giorgi G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009;6:544–52.
[47]
Abolyosr A, Elsagheer GA, Abdel-Kader MS, Hassan AM, Abou-Zeid AMM. Evaluation of the effect of sildenafil and/or doxazosin on benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction. Urol Ann 2013;5:237–40.
[48]
Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51:1717–23.[49]
Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010;28:17–22.
[50]
Regadas RP, Reges R, Cerqueira JBG, et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomized, placebo-controlled clinical trial. Int Urol Nephrol 2013;45:39–43.
[51]
Ozturk MI, Kalkan S, Koca O, Gunes M, Akyuz M, Karaman MI. Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. Andrologia 2012;44(Suppl 1): 791–5.[52]
Gacci M, Vittori G, Tosi N, et al. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsu- losin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 2012;9:1624–33.
[53]
Casabe A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once dailywith finasteride for 6months in men with lower urinary tract symptoms and prostatic enlarge- ment secondary to benign prostatic hyperplasia. J Urol 2014;191: 727–33.[54]
Madani AH, Afsharimoghaddam A, Roushani A, Farzan A, Asadollahzade A, Shakiba M. Evaluation of tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication. Int Braz J Urol 2012;38:33–9.[55]
Yoshimura K, Kadoyama K, Sakaeda T, Sugino Y, Ogawa O, Okuno Y. A survey of the FAERS database concerning the adverse event profiles of alpha1-adrenoreceptor blockers for lower urinary tract symptoms. Int J Med Sci 2013;10:864–9.
[56]
Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyper- plasia: a 9-month, open-label extension study. Urology 2009;74: 1318–22.
[57]
Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral con- trolled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE study and NEPTUNE II open-label extension. Eur Urol 2015;67:262–70.[58]
Takeda M, Nishizawa O, Imaoka T, Morisaki Y, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms in japanese men with benign prostatic hyperplasia: results from a 12-week placebo- controlled dose-finding study with a 42-week open-label exten- sion. Low Urin Tract Symptoms 2012;4:110–9.
[59]
Donatucci CF, Brock GB, Goldfischer ER, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benignE U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 5 7 0 – 5 8 1
580